We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think BionTech want us. Redmile are the matchmakers and Vulpes want a cracking deal out of it for themselves (they still have a decent stake). Sure we may take a hit on the share price short term if we don't get the deal passed this time around, but I am not letting a single share go. Not thinking of trading to de-risk as anything could happen yet. This is just the beginning of a dance that may take a long while...
Crumbs, snap.
A great BB today guys
Remember Vulpes life science fund has investments of about $50 million.... redmile are different league... Vulpes could not compete and if their plan was to take more and more of scancell in dilutive funding for a few million a pop... they would need the sp low!
And Vulpes sank a rising sp.... what was that all about? like they want to keep the sp at a level they want it at... probably so they could eat up more and more for pennies
I think redmile are a fund that like their investments to get deals done with pharmas.... And their backing probably opens all kinds of come back when you are a serious company with serious backing doors that have been closed to scancell.
Also worth noting that Vulpes came in while we were on our knees and have picked up most their shares for an absolute steal. Redmile are willing to put in much bigger money at a much higher price....they really must sniff a huge return here.
We know Avidimab/Glycans deals have been postponed.
Could it also be that Scancell now only want a deal with Biontech after they produce some modi1 data. Again the Biontech deal should have much bigger figures attached to it in the event of good modi1 data.
Scancell can now afford to delay deals on any of their platforms.
WTP
My BioNTech angle... well we know Vulpes did very in-depth due diligence before departing with their pennies... we have not been told that about redmile... so who is it that pointed redmile in our direction? the only connection I can find is BioNTech that may not be the case Cliff may well have impressed them independently at some event... however surely then they would have talked to Sahin... it could equally be Sahin pointed them to us ... I'm not getting at any plots or anything here more a you should take a look at them they have wonderful science that is really undervalued and needs backing.
An example:
'A company developing bispecific antibodies in oncology has received its latest funding boost from the venture capital arms of two large drug companies.
Utrecht, Netherlands-based Lava Therapeutics said Thursday that it had raised $83 million in a Series C financing, led by two new investors – Novo Ventures and Sanofi Ventures – with participation from new investors that included Redmile Group, Ysios Capital and BB Pureos Bioventures. Existing investors Versant, Gilde Healthcare and MRL Ventures Fund also took part in the financing. Novo and Sanofi are respectively the venture capital arms of Danish drugmaker Novo Nordisk and French drugmaker Sanofi.'
Same of course is true of their involvement with BioNTech...the rounds are multi funds funded
redmile are out for redmile but we should not think they are necessarily here to rob us of full value.... infact they could be key to us ever getting it.
Ray, exactly.
Someone (crumbs?) has suggested that BioNtech are the likely matchmakers for Redmile and Scancell?(seeing as it's very unlikely now that Vulpes did).
BioNtech are the only mutual association right?
Well redmile certainly seems well connected in that area as if you look at their recent rounds they do them with other funds.... so it could well be that yes vulpes did not bring in redmile but if vulpes are in a dummy spitting mode (hopefully not and they take it well) then redmile could bring in another fund... also allaying the takeover fears
It occurred to me, even before today's RNS, that Scancell might now be attracting the attention of other fund managers.
Just one to throw in the mix, pure conjecture but...
If Redmile have come into scancell 'unprompted', i.e. not due to anything to do with Vulpes, that means that scancell's own efforts have attracted the attention and cash (in big amounts) of a significant west coast america pharma specialist investor. So if vulpes did get their nose put out of joint by being elbowed out as number one knight in shining armour, can anyone rule out the possibility that some other significant party could be interested enough to take over from Vulpes if it came to that?
Pure theorising, but imo certainly not beyond the realms of reasonable possibility.